TORONTO, ON (November 13, 2012) — The Ontario Institute for Cancer Research (OICR) and MaRS Innovation (MI) today announced $1.5 million in funding from OICR over three years to further develop Cellax™, a nanoparticle drug that could offer an alternative to chemotherapy with fewer side effects.
“Cellax is promising because it provides a more targeted strategy for treating tumours, killing tumour cells while minimizing the effect on healthy tissue,” said Dr. Rima Al-awar, Director, OICR’s Medicinal Chemistry Platform.
Toronto, Ontario – June 7, 2012. The Ontario Institute for Cancer Research (OICR) today announced $1.5 million in funding over three years for the development of a new drug by Toronto-based Fluorinov Pharma, Inc. The drug, called FV-162, is a highly potent, orally-delivered small molecule proteasome inhibitor with significant advantages over drugs currently used to treat multiple myeloma and some forms of Non-Hodgkin’s lymphoma.
Xagenic Inc., a new chip-based diagnostic screening
company, today announced that it raised $10 million in a series A financing.
Investors in the round included CTI Life Sciences Fund L.P., Qiagen N.V. and Ontario
Capital Growth Corporation through its Emerging Technologies Fund. The Ontario
Institute for Cancer Research (OICR) provided initial seed money to develop
Xagenic’s technology, discovered by researchers Shana Kelley and Edward Sargent
at the University of Toronto. With this financing OICR has exercised an option to
acquire shares in Xagenic Inc.
DLVR Therapeutics Inc. (“DLVR”) - a privately-held biotechnology company currently focused on developing oncology
therapeutics based on its proprietary high density lipoprotein-like nanoparticle -
announced today that the Company has completed its seed round investment bringing the
total raised to $2 million in cash and in-kind support. MaRS Innovation joins the University
Health Network (UHN) and the Ontario Institute for Cancer Research (OICR) as investors in